Fogarty Innovation · Aug 2024
Fogarty says Corveus joined its Company Accelerator Program; the piece describes co-founders Tyler Melton and Ishan Kamat, their Biodesign background, and their path toward first-in-human study and commercialization.
Catheter-based solution to treat chronic heart failure.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Corveus Medical is a Houston-based medical device company in the Texas Medical Center developing a minimally invasive, catheter-based nerve ablation therapy for moderate congestive heart failure. The device targets a sympathetic nerve branch implicated in heart-failure progression and includes real-time confirmation of nerve deactivation.
Primary product
A minimally invasive catheter-based nerve ablation system for congestive heart failure
Founded
2021
Headquarters
Houston, Texas, United States (Texas Medical Center)
Team size
1-10
Industry
Medical Equipment Manufacturing
Sub-industry
Cardiovascular medical devices / catheter-based heart-failure therapy
Offices
2450 Holcombe Blvd, Ste X, Houston, TX 77021
Houston, Texas, United States
Business model
Medical device development and commercialization
Funding
Stage
seed
Total raised
$1M
Latest round
Incubator/Accelerator - II · Jul 2023
Jul 2023 · MassChallenge U.S.
Mar 2023 · National Science Foundation
Jun 2022 · MedTech Innovator
Mar 2022 · Y Combinator
People & investors
Leadership
CEO and Co-Founder
Co-Founder and Chief Medical Officer
VP of Engineering
Work & culture
Mission-driven and clinically focused, with public messaging emphasizing patient impact, precision engineering, collaboration with mentors and accelerators, and a path to commercialization.
Product & market
Pricing
Not publicly disclosed.
Differentiators
- —Minimally invasive catheter-based approach
- —Targets a specific sympathetic nerve branch
- —Real-time confirmation of complete nerve deactivation
- —Designed to minimize collateral tissue damage
- —Focused on moderate heart-failure patients with unmet treatment options
Technology
Catheter-based nerve ablation
Sympathetic nerve branch ablation
Venous access via catheter
Real-time confirmation of nerve deactivation
Wix
React
Sentry
Lodash
Google Cloud
Envoy
HTTP/3
HSTS
Open Graph
Customers
Physicians
Cardiologists
Hospitals
Heart-failure programs
Patients with moderate congestive heart failure
Competitors
CVRx
Impulse Dynamics
Corvia Medical
Adona Medical
Reprieve Cardiovascular
Restore Medical
Scale & contact
Estimated revenue
Public third-party estimates conflict; roughly ~$256k to $1M-$10M.
Estimated monthly visits
542
Traffic estimate as of Mar 2026
Latest news
EIN Presswire / Junkosha · Jun 2024
Junkosha named Corveus Medical the category winner in its 2023-2024 Technology Innovator of the Year Award program, highlighting the company’s catheter-based heart-failure device.
Corveus Medical · Jan 2024
Corveus Medical was featured by its own site as a top Y Combinator-backed medical device company for 2024.
Corveus Medical / TMC · Nov 2023
Describes Tyler Melton’s Biodesign journey and states Corveus raised funding after animal studies and later received an NSF SBIR Phase 1 grant and won $35K at Texas A&M New Ventures Competition.
Medsider
Interview summarizes the product, the PMA regulatory strategy, preclinical progress, and Tyler Melton’s founder story.
Jobs and careers at Corveus Medical
0 jobs at Corveus Medical
No open positions
Check back later for new openings